Liver cirrhosis affects serum lactate level measurement while assessing disease severity in patients with sepsis

CURRENT STATUS: POSTED

Chi Yung Cheng
Chang Gung Memorial Hospital Kaohsiung Branch
ORCiD: https://orcid.org/0000-0002-1109-9339

Chia-Te Kung
Chang Gung Memorial Hospital Kaohsiung Branch

Kuan-Han Wu
Chang Gung Memorial Hospital Kaohsiung Branch

Fu-Cheng Chen
Chang Gung Memorial Hospital Kaohsiung Branch

Hsien-Hung Cheng
Chang Gung Memorial Hospital Kaohsiung Branch

Fu-Jen Cheng
Chang Gung Memorial Hospital Kaohsiung Branch

Jyun-Bin Huang
Chang Gung Memorial Hospital Kaohsiung Branch

Chih-Min Su
mitosu@gmail.com Corresponding Author
ORCiD: https://orcid.org/0000-0002-8121-3977

DOI:
10.21203/rs.3.rs-16937/v1

SUBJECT AREAS
   Critical Care & Emergency Medicine

KEYWORDS
   lactate, liver cirrhosis, sepsis, mortality
Abstract

Background

Elevated serum lactate is associated with higher mortality in sepsis, whereas liver dysfunction is associated with higher serum lactate levels. We assessed the predictive ability of serum lactate in patients with liver cirrhosis and sepsis.

Methods

This retrospective study included 12,281 cases of suspected infection with initial serum blood lactate drawn during January 2007-December 2013.

Results

Using one-to-two propensity score matching analysis, 1,053 and 2,106 septic patients with and without underlying liver cirrhosis, respectively, were successfully matched. Lactate levels of survivors and non-survivors were 2.58 and 5.93 mmol/L, respectively, in patients without liver cirrhosis (WLC), 2.96 and 7.29 mmol/L, respectively, in patients with non-decompensated liver cirrhosis (NDLC), and 4.08 and 7.16 mmol/L, respectively, in patients with decompensated liver cirrhosis (DLC). Adjusted odds ratios of an initial serum lactate level >2 mmol/L in 28-day in-hospital mortality were 4.99, 4.74, and 3.33 in the WLC, NDLC, and DLC groups, respectively. In receiver operating characteristic curve analysis, the sensitivity and specificity for predicting mortality were 0.81 and 0.55, respectively, in the WLC group, 0.85 and 0.45, respectively, in the NDLC group, and 0.86 and 0.33, respectively, in the DLC group, using serum lactate levels >2.0 mmol/L.

Conclusions

Serum lactate level can be used to predict the severity of sepsis in patients with liver cirrhosis; however, its specificity would be lower at a cutoff of 2.0 mmol/L.

1. Introduction

Sepsis is a life-threatening organ dysfunction affecting more than 30 million people worldwide annually, with up to 5.3 million deaths [1]. The blood serum lactate level has been recognized as an independent prognostic marker of mortality in patients admitted to the emergency department (ED) with sepsis [2]. As a predictor of mortality for patients with sepsis, the blood serum lactate level has
similar accuracy to the Sequential Organ Failure Assessment (SOFA) score and a superior
discriminative power to the quick SOFA (qSOFA) score [3]. An elevated lactate level is considered to
be due to oxidative stress and anaerobic glycolysis in tissues [4] or metabolic changes through
epinephrine-related sarcolemmal Na+/K+ -ATPase stimulation [5]. The Surviving Sepsis Campaign
and the National Quality Forum suggested using lactate measurement as guidance for the treatment
septic patients [6].
Lactate is mainly metabolized by the liver (around 60%) and kidney (around 30%) [5], and the rate of
lactate clearance in the normal liver exceeds the rate of lactate production of other tissues [7].
Episodes of hepatic decompensation, such as hemorrhage or sepsis, might disturb the equilibrium of
the metabolic acid-base state in cirrhotic patients [8]. Previous studies have implied that critically ill
patients with cirrhosis have higher lactate levels, and early hepatic dysfunction has been related to
elevated serum lactate in acute circulatory failure [9]. Patients with acute liver failure have a
splanchnic release of lactate due to accelerated glycolysis in the splanchnic region [10]. Patients with
chronic liver disease also have higher fasting lactate levels, owing to the alteration of excretory liver
function and portal pressure. Moreover, higher circulating lactate levels are observed in Child class C
patients compared to the other Child classes, suggesting that the lactate level increases with the
degree of cirrhosis [11].
Although previous studies have demonstrated that liver disease is associated with lactate elevation,
the impact of liver cirrhosis on the lactate level for predicting mortality in sepsis remains unknown.
The objective of this study was to determine the influence of liver cirrhosis on serum lactate levels in
predicting the severity of patients with sepsis.
2. Materials And Methods
2.1. Study Design
This was a single-center retrospective cohort study conducted between January 1, 2007 and
December 31, 2013 in Kaohsiung Chang Gung Memorial Hospital, a 2,692-bed acute-care medical
center, and the largest tertiary level care hospital in southern Taiwan. The study protocol was
approved by the Ethics Committee of Chang Gung Memorial Hospital (IRB No.: 103-0053B). Owing to
the retrospective nature of the study, the requirement for written informed patient consent was waived.

2.2. Study setting and population

During the study period, we enrolled all adult patients (≥18 years old) who visited the ED with systemic inflammatory response syndrome (SIRS), received parenteral antibiotics, and had their blood culture and serum lactate levels tested. All patients with liver cirrhosis were enrolled and propensity score matched with age and sex, and the qSOFA score was performed with one to two ratios for control group selection. The study flow chart is shown in Fig. 1. We reviewed electronic medical records, including chart and nursing documentation, and documented the following data: demographic characteristics, vital signs at triage, major preexisting comorbidities, qSOFA scores, laboratory test results, major infection source, mechanical ventilation requirement, and 28-day in-hospital mortality.

The major pre-existing comorbidities and infection sites were determined according to International Statistical Classification of Diseases and Related Health Problems Ninth Revision (ICD-9) coding. The pre-existing comorbidities included liver cirrhosis (571.2, 571.5, 571.6), diabetes mellitus (250.00-250.99), hypertension (401.0–405.9), malignancy (140.00–199.99), cerebrovascular disease (430.00–438.99), congestive heart failure (428.0–428.9), and chronic renal insufficiency (582.00–589.99). The major infection sources included respiratory tract (481.0–486.9), urinary tract (590.00–590.99, 601.0–601.9), intra-abdominal (562.11, 567.0–567.9, 5761, 574.00–574.19, 574.30–574.49, 574.60–574.89), and soft tissue (680.0–686.9, 728.86) infections.

Serum lactate levels were drawn within 6 hours of the ED visit if sepsis was suspected by the ED physician. Serum lactate (mmol/L) levels were examined by serum-based immunoassay (Unicel DxC 880i Synchron, Beckman Coulter Inc., Brea, CA, USA).

2.3. Definitions

To calculate qSOFA scores, one point was awarded for each of the following: systolic blood pressure of 100 mmHg or less, respiratory rate of at least 22 breaths/min, and Glasgow Coma Scale score of up to 13, giving a score of 0-3 [12]. Septic shock was defined as sepsis-induced hypotension despite
adequate fluid resuscitation, in the absence of other causes of hypotension, and required inotropic agent usage [13]. Blood culture with potential contaminating pathogens, such as coagulase-negative Staphylococci, Micrococcus spp., Corynebacterium spp., and Propionibacterium acnes were considered as contaminations [14, 15]. Decompensated liver cirrhosis (DLC) was defined by the chronic liver failure consortium organ failure score, adapted from the original chronic liver failure-sequential organ failure assessment score and specifically designed for use in cirrhotic patients with acute decompensation [16, 17].

2.4. Statistical analysis
Continuous variables are expressed as mean ± standard deviation and were analyzed using a t-test. Categorical variables are shown as actual numbers or percentages and were compared using the Pearson’s chi-squared test or the Fisher’s exact test. For the imbalance between patients with and without liver cirrhosis, propensity scores were estimated with liver cirrhosis as the dependent variable. Covariates, including age, sex, and qSOFA score, were entered into the multivariable models, and matching was performed using the two-to-one matching protocol. Standardized differences of more than 0.10 were considered as evidence of imbalance. Based on the mean standardized differences and variance ratios of the two groups, a total of 1,053 pairs of patients were successfully matched. Area under the receiver operating characteristic curve (AUROC) analysis was performed for serum lactate levels to predict the accuracy for 28-day in-hospital mortality. A regression model was used to calculate the crude odds ratio of serum lactate > 2 to have sepsis-related mortality in each subgroup of patients. Age and sex were further adjusted in the regression model to calculate the adjusted odds ratio. All statistical tests were two-tailed with P < 0.05 considered statistically significant. Statistical analyses were performed using IBM SPSS Statistics for Windows, version 24 (IBM Corp., Armonk, NY, USA).

3. Results
3.1. Baseline Characteristics
During the 7-year study period, 12,281 sepsis patients with initial serum blood lactate drawn were included (Fig. 1). In total, there were 1,053 and 11,228 patients with and without underlying liver
cirrhosis, respectively. As a result of one-to-two propensity score matching, 1,053 and 2,106 patients with and without underlying liver cirrhosis, respectively, were successfully matched. There was no significant difference in age, sex, and qSOFA score between the two groups.

Table 1 shows that the patients with liver cirrhosis had significantly higher incidences of solid tumor, chronic kidney disease, intra-abdomen infection, and bacteremia than those without; whereas patients without liver cirrhosis had higher incidences of hypertension, cerebral vascular disease, heart failure, respiratory tract infection, and urinary tract infection. Furthermore, the liver cirrhosis group had significantly different physiological changes such as lower heart rate, systolic blood pressure, and diastolic blood pressure.
Table 1
Demographic data of infected patients with and without liver cirrhosis

|                                      | Patients without liver cirrhosis n = 2106 | Patients with liver cirrhosis n = 1053 | P-value               |
|--------------------------------------|--------------------------------------------|----------------------------------------|-----------------------|
| Sex (male %)                         | 67.4%                                      | 69.3%                                  | 0.29                  |
| Age (mean ± SD) (years)              | 60.6 ± 16.8                               | 61.1 ± 14.6                            | 0.41                  |
| Vital sign at triage (mean ± SD)     |                                            |                                        |                       |
| Systolic blood pressure              | 129 ± 36                                   | 125 ± 35                               | 0.003*                |
| Diastolic blood pressure             | 78 ± 34                                    | 73 ± 29                                | < 0.001*              |
| Pulse rate                           | 109 ± 319                                  | 103 ± 22                               | < 0.001*              |
| Body temperature                     | 37.6 ± 1.7                                 | 37.5 ± 1.3                             | 0.07                  |
| Respiratory rate                     | 20 ± 4                                     | 20 ± 3                                 | 0.06                  |
| Underlying disease (%)               |                                            |                                        |                       |
| Diabetes mellitus                    | 31.2%                                      | 30.8%                                  | 0.84                  |
| Hypertension                         | 27.3%                                      | 21.3%                                  | < 0.001*              |
| Malignancy                           | 22.6%                                      | 42.1%                                  | < 0.001*              |
| Cerebrovascular disease              | 13.1%                                      | 4.7%                                   | < 0.001*              |
| Congestive Heart failure             | 7.2%                                       | 3.3%                                   | < 0.001*              |
| Chronic kidney disease               | 19.6%                                      | 26.0%                                  | < 0.001*              |
| qSOFA score                          |                                            |                                        |                       |
| 0                                    | 48.4%                                      | 47.3%                                  | 0.40                  |
| 1                                    | 33.9%                                      | 36.7%                                  |                       |
| 2                                    | 14.9%                                      | 13.8%                                  |                       |
| 3                                    | 2.8%                                       | 2.3%                                   |                       |
| Laboratory data (mean ± SD)          |                                            |                                        |                       |
| White blood cell count               | 13.2 ± 10.8                                | 11.1 ± 8.8                             | < 0.001*              |
| Neutrophil (%)                       | 77.9 ± 15.8                                | 78.8 ± 12.5                            | 0.109                 |
| Lymphocyte (%)                       | 12.4 ± 10.9                                | 11.5 ± 9.0                             | 0.029*                |
| Band (%)                             | 1.7 ± 4.2                                  | 2.1 ± 4.6                              | 0.019*                |
| C-reactive protein                   | 125.5 ± 109.4                              | 79.6 ± 81.7                            | < 0.001*              |
| Lactate                              | 2.99 ± 3.17                                | 4.65 ± 5.18                            | < 0.001*              |
| Major infection focus                |                                            |                                        |                       |
| Respiratory tract infection          | 41.5%                                      | 25.4%                                  | < 0.001*              |
| Urinary tract infection              | 21.7%                                      | 17.8%                                  | < 0.01*               |
| Intra-abdomen infection              | 10.1%                                      | 22.4%                                  | < 0.001*              |
| Soft tissue infection                | 9.5%                                       | 7.7%                                   | 0.10                  |
| Bacteremia                           | 14.0%                                      | 24.5%                                  | < 0.001*              |
| Septic shock within 72 hours         | 14.7%                                      | 19.8%                                  | < 0.001*              |
| Intubation within 72 hours           | 20.4%                                      | 22.2%                                  | 0.23                  |
| 28-day in-hospital mortality         | 12.2%                                      | 23.8%                                  | < 0.001*              |

SD: Standard deviation, NS: Not significant
* p < 0.05

With regard to laboratory results of the liver cirrhosis group, the white blood cell count and C-reactive protein level were significantly lower, while the band neutrophil and serum lactate level were significantly higher. Patients in the liver cirrhosis group had a significantly higher septic shock rate within 72 hours (19.8% vs 14.9%; P < 0.001) and a higher 28-day mortality rate (23.8% vs 12.2%; P < 0.001) than those without liver cirrhosis.
3.2. Subgroup Analysis of Serum Lactate Level in Patients with Different Disease Severity

Table 2 and Fig. 2 shows the subgroup analysis of the initial serum lactate level between different disease severity in patients with different stages of liver cirrhosis and those without liver cirrhosis. After categorizing the subgroup patients by hospital mortality, the serum lactate level between survivors and non-survivors was 2.58 vs 5.93 (P < 0.001) in patients without liver cirrhosis (WLC), 2.96 vs 7.29 (P = 0.023) in patients with non-decompensated liver cirrhosis (NDLC), and 4.08 vs 7.16 (P < 0.001) in patients with DLC. Using the qSOFA score to define disease severity, we found that the serum lactate level between the qSOFA < 2 and qSOFA ≥ 2 groups was 2.71 vs 4.27 (P < 0.001) in patients WLC, 3.00 vs 6.37 (P < 0.003) in patients with NDLC, and 4.58 vs 6.50 (P < 0.001) in patients with DLC.

| Lactate (mmol/L) | Survival (n = 1,808) | Non-survival (n = 298) | p | Survival (n = 156) | Non-survival (n = 17) | p | Survival (n = 612) | Non-survival (n = 268) | p |
|------------------|----------------------|-----------------------|---|-------------------|----------------------|---|-------------------|-----------------------|---|
| qSOFA < 2 (n = 1734) | 2.58 ± 2.43 | 5.93 ± 5.51 | < 0.001 | 2.96 ± 3.13 | 7.29 ± 5.93 | 0.023 | 4.08 ± 4.68 | 7.16 ± 6.48 | < 0.001 |
| qSOFA > 2 (n = 372) | 4.27 ± 4.64 | 7.16 ± 5.36 | < 0.001 | 6.37 ± 5.36 | < 0.03 | 4.58 ± 5.08 | 6.50 ± 6.48 | < 0.001 |

Table 3 shows that the adjusted odds ratios of initial serum lactate level > 2 mmol/L in 28-day in-hospital mortality of infected patients were 4.99, 4.74, and 3.33 in the WLC, NDLC, and DLC groups, respectively. Furthermore, severity of liver cirrhosis showed a gradually decreased influence of serum lactate on sepsis-related mortality.
Table 3
Odds ratio of initial serum lactate level in 28-day in-hospital mortality

|                        | Patients without liver cirrhosis (n = 2106) | Non-decompensated liver cirrhosis patients (n = 173) | Decompensated liver cirrhosis patients (n = 880) |
|------------------------|---------------------------------------------|-------------------------------------------------------|-------------------------------------------------|
| Lactate > 2 mmol/L     | Crude odds ratio (95% CI)                    | Adjusted odds ratio (95% CI)                          | Crude odds ratio (95% CI)                        |
|                        | 5.18* (3.75–7.15)                           | 4.99* (3.61–6.90)                                     | 4.85* (1.04–22.59)                               |
|                        | Adjusted odds ratio (95% CI)                 |                                                      | 4.74 (1.00–22.53)                                |
|                        | 3.11* (2.07–4.68)                           |                                                      | 3.33* (2.20–5.04)                                |

CI: Confidence interval
Adjusted age, sex, and qSOFA score
* p < 0.05

Table 4
ROC curve analysis of the initial serum lactate level in predicting 28-day in-hospital mortality

| Group                               | AUC          | 95% CI          | Cut-off point | Sensitivity | Specificity | Youden index |
|-------------------------------------|--------------|-----------------|---------------|-------------|-------------|--------------|
| Patients without liver cirrhosis   | 0.752*       | 0.719–0.786     | 2.00          | 0.81        | 0.55        | 0.36         |
|                                     |              |                 | 4.00          | 0.49        | 0.86        | 0.53         |
| Non-decompensated liver cirrhosis  | 0.790*       | 0.655–0.925     | 2.00          | 0.85        | 0.45        | 0.30         |
|                                     |              |                 | 4.00          | 0.69        | 0.84        | 0.53         |
| Decompensated liver cirrhosis      | 0.696*       | 0.656–0.735     | 2.00          | 0.86        | 0.33        | 0.19         |
|                                     |              |                 | 4.00          | 0.57        | 0.73        | 0.30         |

CI: Confidence interval
* p < 0.05

3.3. Receiver Operating Characteristic Curve Analysis for Lactate in Predicting 28-Day Mortality

In ROC curve analysis (Table 4. Figure 3), the AUROC of serum lactate level in predicting the 28-day mortality was 0.63 (95% CI, 0.57–0.69) in the WLC group, 0.63 in the NDLC group (95% CI, 0.56–0.70), and 0.66 (95% CI, 0.55–0.77) in the DLC group. Using a serum lactate level cut-off point of 2 mmol/L, the sensitivity and specificity for predicting mortality was 0.81 and 0.55 in the WLC group, 0.85 and 0.45 in the NDLC group, and 0.86 and 0.33 in the DLC group, respectively; the sensitivity and specificity became gradually less specific as the liver condition worsened. Using serum lactate levels higher than 4.0 mmol/L as the cut-off point, the sensitivity and specificity for predicting mortality was 0.49 and 0.86 in the WLC group, 0.69 and 0.48 in the NDLC group, and 0.57 and 0.73 in the DLC group, respectively.

4. Discussion

Our study demonstrated that the serum lactate levels in patients with sepsis were significantly higher in liver cirrhotic patients than non-cirrhotic patients, in both survivors and non-survivors. In addition, the serum lactate level increased with increasing liver cirrhosis severity in the survival group. In
subgroup analysis by qSOFA score, the serum lactate level increased with increasing liver cirrhosis severity in both the qSOFA < 2 and qSOFA ≥ 2 groups. In ROC curve analysis, serum lactate could be used to predict sepsis-related mortality in all groups of patients, with the AUC around 0.7; however, with a cut-off point of 2 mmol/L, the liver cirrhotic group demonstrated higher sensitivity but lower specificity compared to those without liver cirrhosis, and the trend appeared more significant with increasing liver cirrhosis severity.

Previous studies demonstrated that hepatic dysfunction is associated with elevated lactate levels, independent from parameters correlated with acute circulatory failure [9]. Despite tissue hypoperfusion, hepatic dysfunction was considered to contribute to blood lactate elevation in patients with shock. Sterling et al. conducted a multicenter randomized clinical trial of 187 patients undergoing early sepsis resuscitation, and revealed that liver dysfunction was significantly associated with higher baseline lactate levels [18]. Although impaired lactate clearance and normalization was observed in advanced liver disease, the result did not translate into a difference in mortality [18]. However, categorized by past medical history, there were only 12 patients with liver cirrhosis in Sterling’s study. Categorized by the liver component of the sequential organ failure assessment score, only 32 patients with moderate to severe liver dysfunction were included. In contrast, the patient number is relatively larger in our study, in that there were 173 patients with NDLC and 879 patients with DLC. Similarly, we also found that the serum lactate level in patients with sepsis was significantly higher in liver cirrhotic patients. For predicting mortality, higher sensitivity and lower specificity were observed in patients with liver cirrhosis, and the trend appeared to correlate with increasing liver cirrhosis severity.

Nowadays, plasma lactate levels are considered to be predictive for prognosis in patients with sepsis [19], pulmonary embolism [20], trauma [21], and in those undergoing cardiac surgery [22]. However, many underlying diseases and medications were found to be associated with an elevated lactate level, including asthma [23], liver dysfunction, kidney disease [24], diabetes on metformin treatment [25], and alcoholism. In septic patients using metformin, the serum lactate level remains useful for predicting mortality, with higher lactate levels (5.9 mmol/L) required to obtain more precise results.
For patients with cirrhosis, many factors may be useful as mortality predictors. In cirrhotic elderly patients admitted to the ICU, the lactate level and Acute Physiology and Chronic Health Evaluation II score were found to be the two best predictive factors for mortality compared to the Child Pugh, Sequential Organ Failure Assessment, and Model for End-stage Liver Disease scores [26]. Similarly, our study implied that although the serum lactate level in patients with sepsis was significantly higher in liver cirrhotic patients, the lactate level remains a useful predictor of mortality. Thus, physicians should be aware of the impact of underlying disease and medication use on lactate levels, and avoid misinterpretations and inappropriate diagnostic or therapeutic activities.

In the non-survival group, the serum lactate level was higher in the NDLC group compared to the DLC group. One possible reason for this result could be that the sample size was relatively small. In the subgroup analysis for non-survival patients, there were only 17 patients in the NDLC group, but 268 patients in the DLC group. The small number of patients in the NDLC group might contribute to a dominant effect of the lactate mean value. In our study, more than 70% of non-survival patients in the NDLC group had lower lactate level than the mean value of the DLC group. Moreover, in-hospital mortality was also affected by diverse factors including nosocomial infections, catheterization during hospitalization, and multiple comorbidities [27–28]. Therefore, the serum lactate level may have different predictive ability in early and late in-hospital mortality. In contrast, when categorizing by qSOFA < 2 or qSOFA ≥ 2, the serum lactate level increased with increasing liver cirrhosis severity; this could be explained by the fact that the timing of the measurement of serum lactate was closer to that of the qSOFA.

This study has several limitations. First, this is a retrospective study, and septic patients whom did not drown serum lactate were excluded. Patients who had lactate drawn were considered to have higher sepsis severity than those who did not. In other words, the patients included in our study tended to have a higher disease severity. Second, we only had initial lactate data instead of serial lactate measurements. Although lactate clearance and normalization during the early resuscitation of sepsis was unavailable, all patients with sepsis received aggressive treatment according to sepsis bundle in our hospital. The majority of patients with sepsis had reduced lactate levels. Finally, the
study was conducted in a single city in Asia, and the results may not be generalizable to other ethnicities. Further studies should be conducted in other regions, with increased patient numbers, and with serial lactate measurement.

5. Conclusions
The serum lactate level in patients with sepsis was significantly higher in liver cirrhotic patients in both survivors and non-survivors. The serum lactate levels in the liver cirrhotic group had higher sensitivity but lower specificity for predicting mortality compared to patients without liver cirrhosis, and the trend appeared more significant with increasing liver cirrhosis severity.

Declarations

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Acknowledgments
We appreciated the Biostatistics Center, Kaohsiung Chang Gung Memorial Hospital for statistics work.

Funding
This research received no external funding

Author information

Affiliations

Department of Emergency Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan

Chi-Yung Cheng; Chia-Te Kung; Kuan-Han Wu; Fu-Cheng Chen; Hsien-Hung Cheng¹; Fu-Jen Cheng; Jyun-Bin Huang ; Chih-Min Su

School of Medicine, Chung Shan Medical University, Taichung, Taiwan

Chih-Min Su

Contributions

CYC and CMS conceived the study. CTK, KHW, and FCC managed the data, including quality control. HHC, FJC, and HYP provided statistical advice on the study design and analyzed the data. CYC, and
CTK chaired the data oversight committee. CYC drafted the manuscript, and all of the authors contributed substantially to its revision. CMS assumed responsibility for the paper as a whole. All authors read and approved the final manuscript.

**Corresponding author**

Correspondence to Chih-Min Su.

**Ethics declarations**

**Ethics approval and consent to participate**

Not applicable

**Consent for publication**

Not applicable

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. American journal of respiratory and critical care medicine 2016;193:259-72.

2. Garcia-Alvarez M, Marik P, Bellomo R. Sepsis-associated hyperlactatemia. Critical care (London, England) 2014;18:503.

3. Liu Z, Meng Z, Li Y, et al. Prognostic accuracy of the serum lactate level, the SOFA score and the qSOFA score for mortality among adults with Sepsis. Scandinavian journal of trauma, resuscitation and emergency medicine 2019;27:51.

4. Andersen LW, Mackenhauer J, Roberts JC, Berg KM, Cocchi MN, Donnino MW. Etiology and therapeutic approach to elevated lactate levels. Mayo Clin Proc 2013;88:1127-40.

5. Levy B. Lactate and shock state: the metabolic view. Current opinion in critical care 2006;12:315-21.
6. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama 2016;315:762-74.

7. Dishart MK, Schlichtig R, Tonnessen TI, et al. Mitochondrial redox state as a potential detector of liver dysoxia in vivo. Journal of applied physiology (Bethesda, Md : 1985) 1998;84:791-7.

8. Funk GC, Doberer D, Kneidinger N, Lindner G, Holzinger U, Schneeweiss B. Acid-base disturbances in critically ill patients with cirrhosis. Liver International 2007;27:901-9.

9. De Jonghe B, Cheval C, Misset B, et al. Relationship between blood lactate and early hepatic dysfunction in acute circulatory failure. Journal of critical care 1999;14:7-11.

10. Clemmesen JO, Hoy CE, Kondrup J, Ott P. Splanchnic metabolism of fuel substrates in acute liver failure. Journal of hepatology 2000;33:941-8.

11. Jeppesen JB, Mortensen C, Bendtsen F, Moller S. Lactate metabolism in chronic liver disease. Scandinavian journal of clinical and laboratory investigation 2013;73:293-9.

12. Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama 2016;315:775-87.

13. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Critical care medicine 2003;31:1250-6.

14. Laupland KB, Church DL. Population-based epidemiology and microbiology of community-onset bloodstream infections. Clinical microbiology reviews 2014;27:647-64.

15. Hall KK, Lyman JA. Updated review of blood culture contamination. Clinical microbiology reviews 2006;19:788-802.

16. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome
that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426-37, 37.e1-9.

17. Kerbert AJC, Verspaget HW, Navarro ÀA, et al. Copeptin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival. Critical Care 2017;21:321.

18. Sterling SA, Puskarich MA, Jones AE. The effect of liver disease on lactate normalization in severe sepsis and septic shock: a cohort study. Clin Exp Emerg Med 2015;2:197-202.

19. Shapiro NI, Trzeciak S, Hollander JE, et al. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Critical care medicine 2009;37:96-104.

20. Vanni S, Viviani G, Baioni M, et al. Prognostic value of plasma lactate levels among patients with acute pulmonary embolism: the thrombo-embolism lactate outcome study. Annals of emergency medicine 2013;61:330-8.

21. Régnier M-AMD, Raux MMDPD, Le Manach YMD, et al. Prognostic Significance of Blood Lactate and Lactate Clearance in Trauma Patients. Anesthesiology: The Journal of the American Society of Anesthesiologists 2012;117:1276-88.

22. Noval-Padillo JA, Serra-Gomez C, Gomez-Sosa L, et al. Changes of lactate levels during cardiopulmonary bypass in patients undergoing cardiac transplantation: possible early marker of morbidity and mortality. Transplantation proceedings 2011;43:2249-50.

23. Lewis LM, Ferguson I, House SL, et al. Albuterol administration is commonly associated with increases in serum lactate in patients with asthma treated for acute exacerbation of asthma. Chest 2014;145:53-9.

24. Bellomo R. Bench-to-bedside review: lactate and the kidney. Critical care (London,
England) 2002;6:322-6.

25. Chen F-C, Kung C-T, Cheng H-H, et al. Metformin Affects Serum Lactate Levels in Predicting Mortality of Patients with Sepsis and Bacteremia. J Clin Med 2019;8:318.

26. Tas A, Akbal E, Beyazit Y, Kocak E. Serum lactate level predict mortality in elderly patients with cirrhosis. Wiener klinische Wochenschrift 2012;124:520-

27. Sheng WH, Wang JT, Lin MS, Chang SC. Risk factors affecting in-hospital mortality in patients with nosocomial infections. Journal of the Formosan Medical Association = Taiwan yi zhi 2007;106:110-8.

28. Abe T, Ogura H, Shiraishi A, et al. Characteristics, management, and in-hospital mortality among patients with severe sepsis in intensive care units in Japan: the FORECAST study. Critical Care 2018;22:322.

Figures
Figure 1

Study flow chart

Patients were admitted to the ED from 2007 to 2013
(n=902,247)

Age over 18 years old, parental antibiotic use, and blood culture collected and serum lactate drawn
(n=12,281)

Patients without liver cirrhosis
(n=11,228)
Patients with liver cirrhosis
(n=1,053)

Propensity score matching with age, sex, and qSOFA score 1:2

Patients without liver cirrhosis
(n=2,106)
Patients with liver cirrhosis
(n=1,053)
Figure 2

Subgroup analysis by survival and qSOFA score. (a) The serum lactate level was higher in patients with liver cirrhosis than WLC group, and correlated with severity of liver cirrhosis in the survival group. In the non-survival group, the serum lactate level was higher in liver cirrhosis than WLC group, but the NDLC group had higher lactate levels than the DLC group. (b) The serum lactate level increased with liver cirrhosis severity in both the qSOFA <2 and qSOFA ≥2 groups.

Figure 3

Receiver operating characteristic curve analysis of serum lactate levels for predicting 28-day mortality. (a) without liver cirrhosis, (b) non-decompensated liver cirrhosis, and (c) decompensated liver cirrhosis.
